PPARG and heart failure: Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhances insulin sensitivity and reduces hepatic triglyceride accumulation, though its use is limited by adverse effects such as fluid retention and an increased risk of heart failure, and a higher incidence of fractures in the elderly population.